Head-to-head · Cost-Efficiency Index
Peter MD vs DoctorAdam
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Peter MD
Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Visit Peter MDDoctorAdam
Shoppers who want a needle-free oral GLP-1 with named prescribers, in the 47 states DoctorAdam actually serves.
Visit DoctorAdamThe verdict
DoctorAdam takes it, leading the Cost-Efficiency Index 74 to 72. DoctorAdam is a Shopify-storefront telehealth company selling compounded oral (sublingual) and injectable semaglutide and tirzepatide plus NAD+/glutathione add-ons, prescribed by a named roster of six MD/NP prescribers. Peter MD still earns a C — Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs DoctorAdam.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Peter MD | DoctorAdam |
|---|---|---|
| Cost-Efficiency Index | 72/100 | 74/100 |
| Semaglutide / mo | $149/mo first-time (Level 1), $139/mo returning (Level 2) | $129/mo (starting dose, compounded oral) |
| Tirzepatide / mo | $149 first month, then $249/mo billed quarterly | $199/mo (starting dose, compounded oral) |
| Semaglutide / yr (modeled) | $1,788 | $1,548 |
| Tirzepatide / yr (modeled) | $2,988 | $2,388 |
| Coverage | Varies by treatment — excluded in several states (marketing pages list AL/ID; the affiliate program's own disclosure is wider) | 44 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #54 | #58 |
Peter MD
72/100Where the value is
- Broadest cross-category catalog in this ranking under one account: TRT, ED, non-GLP-1 weight loss, GLP-1 (semaglutide/tirzepatide), men's hair loss and NAD+, plus sermorelin
- Physician-prescribed, nationwide telehealth brand operating since 2021 (Miami, FL HQ)
- Sermorelin ($585 for a 12-week supply, ~$195/mo) and NAD+ ($369 for an 8-10 week supply, ~$147-184/mo) sit in the same catalog as the GLP-1 line for anyone consolidating multiple scripts
The tradeoffs
- Tirzepatide's $149 first-month rate steps up to $249/mo billed quarterly — the number that matters for budgeting is the renewal price, not the headline
- Semaglutide pricing depends on tier: $149/mo first-time (Level 1) vs $139/mo returning (Level 2), with different total costs ($447 vs $834) over different supply windows, so the all-in cost is not a single number
DoctorAdam
74/100Where the value is
- Names six actual prescribers with credentials — unusually transparent for a Shopify-based storefront
- Needle-free oral tablet option for both semaglutide (from $129) and tirzepatide (from $199)
- Flat 'no hidden fees' pricing framing, with free 2-3 business day shipping
The tradeoffs
- The homepage claims 'Delivery Across All 50 States' but the site's own FAQ state list is 47 states plus DC — New Jersey, Mississippi, and Alaska are excluded
- Injectable dose-tier pricing could not be verified live in this pass (repeated 429 errors on the product pages); only the oral 'from' price is confirmed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.